Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HER2 Amplification Clear all
Active, not recruiting Phase 2 Interventional Results available

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

NCT06136897
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional Results available

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

NCT04209465
View directory record Official record
Conditions
Solid Tumor
Interventions
BDTX-189
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Active, not recruiting Phase 1 Interventional

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Interventions
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Drug
Lead sponsor
Enliven Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Plantation, Florida • St Louis, Missouri • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

NCT01828021
View directory record Official record
Conditions
Breast Cancer
Interventions
Margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Active, not recruiting Phase 3 Interventional

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
89
States / cities
Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

NCT00320385
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
87
States / cities
Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518
View directory record Official record
Conditions
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions
PRT2527
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT05252416
View directory record Official record
Conditions
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Not applicable Interventional Results available

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

NCT03137693
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
Interventions
Standard of Care Schedule Variation: SABR, Breast-conserving Surgery
Other · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 22, 2026, 5:05 AM EDT
Completed No phase listed Observational

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

NCT05902494
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Completed No phase listed Observational

Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections

NCT01066507
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Applied Spectral Imaging Ltd.
Industry
Eligibility
21 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Lakewood, New Jersey • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 22, 2026, 5:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

NCT06726148
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Interventions
ECI830, ribociclib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

NCT03365882
View directory record Official record
Conditions
Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pertuzumab, Trastuzumab, HER-2 testing
Biological · Drug · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
786
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Suspended Phase 1 Interventional

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

NCT04650451
View directory record Official record
Conditions
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
Interventions
chimeric antigen receptor (CAR) T cell therapy
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

NCT00479856
View directory record Official record
Conditions
Relapsed Breast Cancer, Neoplasms, Breast
Interventions
Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

NCT00748709
View directory record Official record
Conditions
Neoplasms
Interventions
BIBW 2992 (Afatinib)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 22, 2026, 5:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700
View directory record Official record
Conditions
Solid Tumors
Interventions
ORIC-114, Chemotherapy drug
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Recruiting Phase 2 Interventional

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
158
States / cities
Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

NCT00047255
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, Docetaxel, trastuxumab
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 22, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

NCT01774851
View directory record Official record
Conditions
HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Interventions
MM-111, Paclitaxel, Trastuzumab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 22, 2026, 5:05 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

NCT03783936
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
Interventions
Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Drug
Lead sponsor
Ashwin Somasundaram
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 22, 2026, 5:05 AM EDT
Not listed Phase 1 Interventional

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

NCT04660929
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 22, 2026, 5:05 AM EDT